Novavax and Johnson & Johnson (J&J) have released preliminary efficacy data from their large scale phase 3 trials. Their efficacy estimates present critical insights for the potential immune-resistance of these variants.
Novavax And Johnson & Johnson’s Vaccines Are Less Effective Against The UK And South African Variants
